Skip to main content

Table 2 Baseline demographic and clinical characteristics (postmatching)

From: Costs associated with failure to respond to treatment among patients with rheumatoid arthritis initiating TNFi therapy: a retrospective claims analysis

  Responders (n = 2337) Nonresponders (n = 2337) p Valuea Standardized differenceb
Female sex, n (%) 1655 (70.8%) 1659 (71.0%) 0.900 0.00
Age at index date, years, mean (SD) 52.3 (11.30) 52.0 (10.66) 0.466 0.02
Geographic region, n (%)
 Northeast 348 (14.9%) 327 (14.0%) 0.382 0.03
 South 689 (29.5%) 609 (26.1%) 0.009 0.08
 Midwest 731 (31.3%) 786 (33.6%) 0.086 0.05
 West 453 (19.4%) 493 (21.1%) 0.145 0.04
 Unknown 116 (5.0%) 122 (5.2%) 0.690 0.01
Health plan type, n (%)
 HMO 590 (25.2%) 546 (23.4%) 0.133 0.04
 PPO 1604 (68.6%) 1642 (70.3%) 0.228 0.04
 CDHP 143 (6.1%) 149 (6.4%) 0.717 0.01
Any Medicare plan (Medicare Advantage or Medicare Supplemental plus Part D), n (%) 182 (7.8%) 182 (7.8%) 1.000 0.00
TNFi agent on index fill, n (%)
 Adalimumab 586 (25.1%) 579 (24.8%) 0.813 0.01
 Certolizumab pegol 24 (1.0%) 43 (1.8%) 0.019 0.07
 Etanercept 1418 (60.7%) 1418 (60.7%) 1.000 0.00
 Golimumab 56 (2.4%) 43 (1.8%) 0.187 0.04
 Infliximab 253 (10.8%) 254 (10.9%) 0.962 0.00
Prescribing physician specialty on index TNFi claim, n (%)
 Rheumatology 1872 (80.1%) 1864 (79.8%) 0.770 0.01
 PCPc 35 (1.5%) 38 (1.6%) 0.723 0.01
 Other 47 (2.0%) 40 (1.7%) 0.449 0.02
 Unknown 383 (16.4%) 395 (16.9%) 0.637 0.01
QCI, mean (SD) 1.5 (1.03) 1.5 (0.99) 0.977 0.00
CIRAS, mean (SD) 6.6 (1.73) 6.5 (1.68) 0.043 0.02
Targeted comorbidities of interest, n (%)
 Chronic respiratory/pulmonary conditions 305 (13.1%) 365 (15.6%) 0.012 0.07
 CVDd 197 (8.4%) 206 (8.8%) 0.592 0.02
 Diabetes 280 (12.0%) 250 (10.7%) 0.166 0.04
 Dyslipidemia 789 (33.8%) 771 (33.0%) 0.577 0.02
 Fibromyalgia 316 (13.5%) 392 (16.8%) 0.002 0.09
 Fragility fractures (closed) 34 (1.5%) 37 (1.6%) 0.720 0.01
 GI ulcer 23 (1.0%) 26 (1.1%) 0.667 0.01
 Hypertension 809 (34.6%) 880 (37.7%) 0.031 0.06
 Low-back pain 461 (19.7%) 594 (25.4%) <0.001 0.14
 Mental health issues 476 (20.4%) 471 (20.2%) 0.856 0.01
 Osteoarthritis 892 (38.2%) 969 (41.5%) 0.021 0.07
 Osteoporosis 231 (9.9%) 254 (10.9%) 0.270 0.03
  1. Abbreviations: ACS Acute coronary syndrome, CDHP Consumer-driven health plan, CHD Coronary heart disease, CIRAS Claims-based index for rheumatoid arthritis severity, CVD Cardiovascular disease, GI Gastrointestinal, HMO Health maintenance organization, MI Myocardial infarction, PAD Peripheral arterial disease, PCP Primary care physician, PPO Preferred provider organization, QCI Quan-Charlson comorbidity index, TIA Transient ischemic attack, TNFi Tumor necrosis factor inhibitors
  2. a χ2 tests were used to determine statistical differences across categorical variables; t tests were used for continuous variables
  3. b Standardized difference = difference in means or proportions divided by standard error, in absolute value
  4. c PCP includes family/general practice and internal medicine
  5. d CVD includes ACS (MI and unstable angina), CHD with or without history of MI, ischemic stroke/TIA, PAD, and ventricular arrhythmia